Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889990 | 1.00 | FPR2 (0.80) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL14937931 | 0.89 | FPR2 (1.00) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL19566147 | 0.89 | FPR2 (0.82) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL22506221 | 0.89 | FPR2 (1.00) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL14948919 | 0.89 | FPR2 (1.00) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL23114219 | 0.88 | FPR2 (0.72) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL14889843 | 0.88 | FPR2 (0.72) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL21545854 | 0.84 | FPR2 (0.78) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL14889947 | 0.84 | FPR2 (0.74) | FPR2POLBPKMALDH1A1MAPT | |
| SCHEMBL22175125 | 0.84 | FPR2 (0.74) | FPR2POLBPKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088385-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2776389-B1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8816076-B2 | Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8541577-B2 | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013070600-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885POLB 4372/4885PKM 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.